StockData

Alnylam Pharmaceuticals vs BeOne Medicines

ALNY and ONC side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ALNY and ONC compare

BeOne Medicines is the larger company, worth 29 times as much as Alnylam Pharmaceuticals ($611B against $21.0B).

On earnings, Alnylam Pharmaceuticals is cheaper: it trades at 8.1× trailing earnings, against 961× for BeOne Medicines.

Alnylam Pharmaceuticals grew revenue faster over the last twelve months (56.2% versus 34.3% for BeOne Medicines).

Alnylam Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of 52.8% compared with 10.7% at BeOne Medicines.

BeOne Medicines scores higher on the StockData Score (13 against 10 for Alnylam Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricALNYONC
Size and price
Market cap$21.0B$611B
Share price$156.50$413.26
Change, 1 year−65.2%13.0%
Change, 5 years−17.0%18.9%
Beta (5Y)0.920.64
Employees2,50012K
StockData Score
Total score1013 (better)
Valuation score3 (better)0
Growth score24 (better)
Performance score34 (better)
Health score25 (better)
Dividend score00
Valuation
P/E8.1× (better)961×
P/S4.2× (better)99.7×
P/B5.8× (better)118×
EV/EBITDA16.8× (better)563×
P/FCF26.0× (better)459×
FCF yield3.8% (better)0.22%
Fair value$296.91$15.47
Margin of safety47.3% (better)−2571%
Growth
Revenue growth (TTM)56.2% (better)34.3%
Revenue growth, 5Y average49.8%76.8% (better)
Net income growth (TTM)2137%–
EPS growth (TTM)2308%–
Profitability
Gross margin77.4%88.9% (better)
Operating margin19.5% (better)15.1%
Net margin52.8% (better)10.7%
FCF margin16.1%21.7% (better)
Return on equity127% (better)14.7%
Return on invested capital–43.7%
Financial health
Debt / equity–0.22
Net debt / EBITDA–−3.67
Interest coverage3.2×8.7× (better)
Current ratio2.483.40 (better)
Altman Z-score3.6292.06 (better)
Piotroski F-score67 (better)
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions99.7%2.4%
Held by insiders0.49%14.2%
Insider net buying, 12 months−$26.3M (better)−$384M
Short interest, % of float4.1%–

Go deeper

Other comparisons

For information only, not investment advice. Check the source filings before relying on any figure.